Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observation of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
ChiCTR1800015826Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoints: Minnesota Living with Heart Failure Questionnaire, Blood pressure and 2 more. Started Apr 2018; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR1800015826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015826.